INTRODUCTION

Top Abstract Introduction Materials and Methods Results Discussion References

Nuclear factor B (NF-B) represents a family of eukaryotic transcription factors participating in the regulation of various cellular genes involved in the immediate early processes of immune, acute-phase, and inflammatory responses as well as genes involved in cell survival (for recent reviews, see references 23, 24, and 59). NF-B also serves as a key cellular transcriptional activator of a number of human viruses, most notably human immunodeficiency virus type 1 (HIV-1) (30, 34, 35, 48, 53). In mammalian cells, five members of the NF-B family have been characterized, including p50, p52, RelA (previously termed p65), RelB, and c-Rel. The different NF-B proteins have significant sequence homology in an N-terminal region (~300 amino acids), termed the Rel-homology domain (RHD). The RHD contains sequences mediating DNA binding, dimerization, and nuclear translocation functions (47, 56).

In most cell types, the pleotropic-inducible form of NF-B is a heterodimer composed of p50 and RelA (4). RelA contains a C-terminal transactivation domain in addition to the N-terminal RHD, thus serving as a critical transactivation subunit of NF-B (6, 42, 45). p50 lacks a transactivation domain, and it is believed to serve as a regulatory subunit modulating the DNA binding affinity of RelA (6, 42, 45). The p50-RelA NF-B heterodimer is normally sequestered in the cytoplasmic compartment by physical association with inhibitory proteins, including IB and related proteins (5). IB specifically binds to and masks the nuclear localization signals (NLS) of RelA and p50, thereby preventing the nuclear translocation of the NF-B heterodimer (7, 21, 25, 61). The latent cytoplasmic NF-B RelA-p50 complex can be posttranslationally activated by a variety of cellular stimuli (2, 28), which trigger site-specific phosphorylation of IB (9, 10, 16, 54) by a multisubunit IB kinase (IKK) (12, 14, 17, 33, 38, 41, 58, 60, 62). The phosphorylated IB becomes rapidly ubiquitinated and degraded by the proteasome complex (11, 16, 40, 44). Following IB degradation, the NF-B heterodimer is rapidly translocated to the nucleus, where it activates the transcription of target genes.

Although the mechanism underlying the inducible degradation of IB has been well studied, it has remained unclear whether the cytoplasmic and nuclear shuttling of NF-B is under the control of additional mechanisms. We report here that the RelA subunit of NF-B contains a leucine-rich sequence homologous to the recently characterized nuclear export signal (NES) (22). Due to the presence of this NES-like sequence, a large proportion of RelA is localized in the cytoplasm even in the absence of the inhibitory protein IB. Interestingly, when coexpressed with p50, the cytoplasmic expression of RelA is completely inhibited, leading to the nuclear accumulation of both RelA and p50. These results strongly suggest that subcellular localization of the RelA subunit of NF-B is under the regulation of both cis-acting sequences and p50.

	MATERIALS AND METHODS

Top Abstract Introduction Materials and Methods Results Discussion References

Plasmid constructs. The cDNA expression vectors encoding wild-type RelA (RelA WT) and its truncation mutants were generated by PCR amplification of human RelA cDNA and subsequent cloning of the PCR products into the pCMV4 mammalian expression plasmid (21). The truncation mutants are named based on the amino acid residues retained in the constructs. For example, RelA(31-551) contains amino acids 31 to 551 of RelA, while RelA(1-450) contains amino acids 1 to 450 of RelA. The RelA(1-450)NES was created by site-directed mutagenesis (Stratagene) to delete four amino acids (L₄₄₀, L₄₄₁, Q₄₄₂, and L₄₄₃) from the core region of the RelA NES site. The sense oligonucleotide primer sequence used in the site mutagenesis was GGA ACG CTG TCA GAG GCC CAG TTT GAT GAT GAA GAC CTG. To generate RelA(1-420)-NES, a short DNA fragment covering the NES region of RelA was fused to the C terminus of RelA(1-420). RelA-NLS was constructed by fusing a copy of the simian virus 40 large T antigen NLS (PKKKRKV) to the N terminus of RelA by PCR. To generate RelA-NLS-NES, RelA-NLS was subjected to internal deletion to remove the four amino acids (L₄₄₀, L₄₄₁, Q₄₄₂, and L₄₄₃) from the core region of the RelA NES. p50-GFP was constructed by cloning a HindIII/RsaI fragment of pCMV4-p50 to the pEGFP-N2 plasmid (ClonTech, Inc.) upstream of the green fluorescent protein (GFP) coding region. p50-GFP-NES was generated by inserting the RelA NES to the C terminus of the GFP. pCMV4-IB has been reported previously (21), and IB-GFP was constructed by inserting GFP to the CMV4-IB vector upstream of the IB. The B-TATA-luc reporter plasmid has been reported previously (21).

Immunoblotting and immunofluorescence assays. Monkey kidney COS cells were cultured in Iscove's medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine, and antibiotics. For immunoblotting assays, the cells were transfected in six-well plates as previously described (21). Whole-cell extracts were subjected to Western blot assays (21). For immunofluorescence assays, the cells were seeded on four-well chamber slides and transfected by the DEAE-dextran method (26). In the single transfections, 0.25 µg of the indicating cDNA expression vectors was used. For the double transfections, 0.25 µg of RelA and 0.5 µg of p50-GFP (or p50-GFP-NES) were used. After 48 h, recipient cells were lysed in ELB cell lysis buffer (21) and then subjected to immunoblotting with the indicated antibodies. For immunofluorescence assays, COS cells were seeded onto coverslips and transfected by the DEAE-dextran method. After 48 h, the cells were fixed, permeabilized, and sequentially incubated with the indicated primary antibodies, followed by donkey anti-rabbit immunoglobulin (Ig) covalently coupled to Texas red dye (21). The subcellular localization of transfected proteins was detected by fluorescence microscopy with a rhodamine filter by using an Olympus BH-2 fluorescence microscope. Digital images were collected by Optimas 6.2 and then transferred to Adobe Photoshop 4.0. Expression of the GFP fusion proteins were visualized directly with a fluorescein isothiocyanate (FITC) filter. Cells were also counterstained with 1 µg of Hoechst 33258 (added together with the secondary antibody; Sigma) per ml and visualized with a UV filter. For inhibition of protein nuclear export, transfected cells were incubated with 40 ng of leptomycin B (LMB) per ml for 6 h prior to immunofluorescence staining.

Luciferase reporter gene assays. COS cells were transfected, in 24-well plates, with 50 ng of the B-TATA-luc reporter (21) together with 100 ng of cDNA expression vectors encoding wild-type RelA or the indicated RelA truncation mutants. After 40 to 48 h of transfection, the recipient cells were lysed in a reporter lysis buffer (Promega). Luciferase activity was detected by mixing 5 µl of extract with 25 µl of luciferase substrate (Promega) and measured with a single photon channel of a scintillation counter (Beckman).

	RESULTS

Top Abstract Introduction Materials and Methods Results Discussion References

Cytoplasmic expression of RelA is mediated by a C-terminal region adjacent to its transactivation domain. Previous studies demonstrate that when expressed in COS cells, a large proportion of RelA is retained in the cytoplasm, while the p50 subunit is exclusively expressed in the nucleus (21). Since RelA is a transactivator of the gene encoding its inhibitor IB (13, 31, 46, 51), one potential mechanism mediating the cytoplasmic expression of RelA may be the induction of endogenous IB. To examine this possibility, we first determined whether the cytoplasmic expression of RelA was dependent on its transactivation activity. RelA WT and its truncation mutants (Fig. 1A) were subjected to indirect immunofluorescence and parallel transactivation assays. As expected, RelA WT was predominantly located in the cytoplasm (Fig. 1B), and the cytoplasmic localization of RelA was correlated with its transactivation function (Fig. 1C and D, lanes 2). However, an N-terminally truncated form of RelA [RelA(31-551)] defective in DNA binding (21) still exhibited a strong cytoplasmic expression activity, generating a whole-cell distribution pattern (Fig. 1B). As previously demonstrated (21), this RelA mutant failed to transactivate the B-TATA-luc reporter (Fig. 1C) and to induce the expression of endogenous IB (Fig. 1D, lane 4). Thus, IB inhibition may not be the only mechanism mediating the cytoplasmic expression of RelA. In further support of this notion, removal of the C-terminal transactivation domain of RelA [RelA(1-450)] (Fig. 1A) did not significantly alter its subcellular localization pattern (Fig. 1B), although this truncated form of RelA completely lost its transactivation activity (Fig. 1C and D, lanes 3). To further examine the mechanism regulating the subcellular localization of RelA, additional truncation mutants of RelA were subjected to the immunofluorescence assays. Interestingly, a deletion of 30 amino acids or more beyond the transactivation domain generated RelA mutants [RelA(1-420) and RelA(1-312)] exhibiting predominantly nuclear expression (Fig. 1B). Together, these results strongly suggest that the cytoplasmic expression of RelA involves not only IB inhibition but also a regulatory mechanism mediated by a C-terminal sequence element located adjacent to its transactivation domain.

View larger version (66K): [in this window] [in a new window]   FIG. 1.   Cytoplasmic expression of RelA is mediated by its C-terminal sequences located beyond the transactivation domain. (A) Primary domain structure of RelA WT and its truncation mutants. The locations of the DNA binding domain (DB) and the transactivation domain (TA) are presented according to previous studies (6, 21, 45). The DNA binding and transactivation activities of the mutants were as determined in a previous study (21) and for Fig. 1C and D. (B) Immunofluorescence assays to determine the subcellular localization of RelA WT and truncation mutants. COS cells were transfected with the indicated cDNA expression vectors. After 48 h, the transfected cells were subjected to indirect immunofluorescence assays with antisera recognizing the C terminus (WT and 31-551) or N terminus (1-450, 1-420, and 1-312) of RelA (21) and Texas red-conjugated anti-rabbit Ig secondary antibody (upper panels). To localize the nuclei of the transfected cells, the cells were counterstained with Hoechst 33258 and visualized with a UV filter (lower panels). (C) Luciferase reporter gene assay determining the transactivation activity of RelA and its truncation mutants. COS cells were transfected with the B-TATA-luc reporter plasmid together with either an empty vector, cDNA expression vectors encoding the wild type (WT), or the indicated truncation mutants of RelA. Luciferase activity is presented as the fold induction relative to the basal level measured in cells transfected with the empty vector. (D) Immunoblotting analysis of the whole-cell extracts isolated from COS cells transfected with either an empty vector or cDNA expression vectors encoding RelA WT or its truncation mutants [RelA(1-450) and RelA(31-551)]. Immunoblotting was performed with antisera that reacted with the N terminus (lanes 1 to 3) or C terminus (lane 4) of RelA or IB. The RelA and its truncation mutants are labeled with a bracket, and IB is indicated by an arrow. Only RelA WT induces expression of endogenous IB.

A putative NES sequence promotes cytoplasmic expression of RelA. After analyzing the sequence located between amino acids 420 and 450 of RelA, we observed a leucine-rich sequence element (amino acids 436 to 445) homologous to the NES motifs identified from a number of proteins, such as the protein kinase inhibitor alpha and beta subunits (57), the HIV-1 Rev protein (18), and the proto-oncogene product c-Abl (52) (Fig. 2). An important structural feature of NES is the presence of four conserved hydrophobic amino acid residues (22). The NES-like sequence of RelA contains all these conserved residues (Fig. 2). To determine the potential role of this putative NES in the cytoplasmic expression of RelA, a RelA mutant [RelA(1-450)NES] was generated by deleting four amino acid residues (L₄₄₀, L₄₄₁, Q₄₄₂, and L₄₄₃) from this leucine-rich segment of RelA(1-450). As shown in Fig. 3A, this modification completely altered the subcellular localization pattern of RelA(1-450) (compare panels a and b). While the unmodified RelA(1-450) mutant exhibited a whole-cell expression pattern, the NES-deficient mutant, RelA(1-450)NES, was located predominantly in the nucleus (Fig. 3). Thus, the NES-like sequence is responsible for the whole-cell expression of RelA(1-450). To examine whether this NES also functions in the full-length RelA, we first generated a RelA containing an N-terminal-tagged NLS derived from the simian virus 40 large T antigen NLS (RelA-NLS). Since the N terminus of RelA is not masked by IB (3, 27, 29), the nuclear import of this N-terminal-tagged RelA should not be affected by IB. Interestingly, a significant amount of RelA-NLS was still located in the cytoplasm even though it was fused with a strong NLS (Fig. 3A). Furthermore, the cytoplasmic localization pattern of RelA-NLS was completely abolished when the NES of RelA was deleted (Fig. 3A). These results suggest that the NES of RelA functions in both the truncated and full-length forms of RelA.

View larger version (25K): [in this window] [in a new window]   FIG. 2.   Identification of a NES-like sequence in RelA. The upper panel shows the amino acid sequence of the C-terminal region of RelA mediating its cytoplasmic distribution. The NES-like sequence is indicated. The lower panel shows the sequence homology of the RelA NES with the NES characterized from various other proteins, including the alpha and beta subunits of the protein kinase inhibitor (PKI) (57), the HIV Rev protein (18), and c-Abl (52). The four hydrophobic amino acids, most of which are leucines, are bold and underlined. The NES of RelA is located between amino acids 436 and 445.

View larger version (34K): [in this window] [in a new window]   FIG. 3.   The NES-like sequence of RelA promotes cytoplasmic localization of RelA as well as p50. (A) COS cells were transfected with cDNA expression vectors encoding the RelA proteins indicated below each of the panels. The cells were stained with anti-RelA plus Texas red-conjugated rabbit IgG (RelA), counterstained with Hoechst, and visualized as described in the legend for Fig. 1B. (B) COS cells were transfected with cDNA expression vectors encoding the proteins indicated below the panels. The cells were stained with an anti-RelA antiserum and Texas red-conjugated rabbit IgG. The expression of the RelA mutants (a and b) was visualized with a rhodamine filter (RelA), whereas the expression of p50-GFP fusion proteins (c and d) was visualized via the autofluorescence of GFP by using an FITC filter (GFP). The nuclei of the cells were visualized by DNA staining with Hoechst (DNA).

LMB inhibits the cytoplasmic distribution of RelA. Recent studies demonstrate that the nuclear export of NES-containing proteins is mediated by a receptor protein termed CRM1 (19, 20, 36, 37, 49). A drug, LMB, has been shown to specifically bind CRM1, thereby inhibiting NES-mediated nuclear protein export (20). To further determine whether the cytoplasmic expression of RelA is mediated through its continuous nuclear export, the effect of LMB on the subcellular localization of RelA was examined. Incubation of the RelA-transfected cells with LMB for 6 h markedly inhibited the cytoplasmic distribution of RelA, leading to its nuclear accumulation (Fig. 4A). A shorter period (1 to 2 h) of LMB treatment also yielded a partial effect on RelA subcellular localization, but a maximal effect was detected at 6 h (data not shown), which was also the time period used in other studies (52). Parallel immunoblotting assays revealed that LMB moderately inhibited the inducible expression of IB in cells transfected with RelA WT (Fig. 4B and C). However, the IB inhibition does not seem to be a major mechanism by which LMB blocks the cytoplasmic expression of RelA. As shown in Fig. 4A, LMB also efficiently blocked the cytoplasmic expression of two truncated forms of RelA [RelA(1-450) and RelA(31-551)], which were defective in IB induction (Fig. 1D), as well as p50-GFP-NES. Thus, it is likely that LMB inhibited the nuclear export of these proteins containing the RelA NES.

View larger version (96K): [in this window] [in a new window]   FIG. 4.   Cytoplasmic expression of RelA is sensitive to a nuclear export inhibitor, LMB. (A) COS cells were transfected with cDNA expression vectors encoding the indicated RelA proteins or p50-GFP-NES. After 48 h, the cells were either not treated (NT) or treated for 6 h with 40 ng of LMB per ml, followed by immunofluorescence staining. The RelA and its mutants were stained with anti-RelA and Texas red-conjugated rabbit IgG and were visualized with a rhodamine filter, while the p50-GFP-NES proteins were directly visualized with an FITC filter. Nuclei of the cells were stained with Hoechst, and the images are shown in the lower panels. (B and C) COS cells were transfected with RelA WT, and 48 h posttransfection, the cells were incubated for 6 h with the indicated amounts of LMB. The expression of the transfected RelA and the induced endogenous IB was detected by a Western blot assay with anti-RelA and anti-IB (B). The intensity of the protein bands was quantitated by densitometry and presented as a percentage of that from the untreated cells (C).

p50 prevents the cytoplasmic expression of RelA mediated by the putative NES. Under physiological conditions, nuclear RelA is present predominantly as a heterodimer with p50. The p50 protein is known to serve as a regulatory subunit modulating the DNA binding affinity of RelA (47). To examine whether p50 also regulates the cytoplasmic and nuclear shuttling of RelA, immunofluorescence assays were performed to examine the effect of p50 on RelA subcellular localization. For these studies, COS cells were transfected with RelA together with cDNA expression vectors encoding either GFP or the p50-GFP fusion protein (Fig. 5A). Expression of RelA in the cells was detected by immunostaining with anti-RelA followed by Texas red-conjugated anti-rabbit IgG, whereas the expression of GFP and p50-GFP was directly visualized via the autofluorescence of GFP (Fig. 5A). As expected, coexpression with GFP did not change the subcellular localization of RelA, which was still largely located in the cytoplasm (Fig. 5A). Interestingly, when RelA was expressed together with p50-GFP, these two NF-B subunits were colocalized to the nucleus (Fig. 5A). Similar results were obtained with a p50 lacking GFP (data not shown). The nuclear localization of RelA was specifically triggered by expression of p50-GFP in the same cells, since RelA was still retained in the cytoplasm in cells lacking p50-GFP expression (Fig. 5A). Similarly, the cytoplasmic distribution of RelA(1-450) was also inhibited when this truncated form of RelA was coexpressed with p50 (data not shown). Thus, the p50 subunit of NF-B promotes nuclear accumulation of RelA. To determine whether this specific property of p50 is due to its lack of nuclear export activity, studies were performed to examine the effect of p50-GFP-NES on the subcellular localization of RelA. Unexpectedly, attachment of the RelA NES to p50 did not affect its ability to induce the nuclear accumulation of RelA (Fig. 5B). Furthermore, the NES-mediated cytoplasmic expression of p50-GFP-NES was also inhibited when this fusion protein was coexpressed with RelA (Fig. 5B). These results suggest that lack of a NES is unlikely the molecular basis of p50-mediated stimulation of RelA nuclear accumulation. Further studies showed that the C-terminal truncation mutants RelA(1-312) and RelA(1-420) also induced the nuclear expression of RelA (data not shown). Thus, it seems likely that the lack of the long RelA C-terminal tail sequence in p50 contributes to its specific function in promoting RelA nuclear localization.

View larger version (30K): [in this window] [in a new window]   FIG. 5.   p50 induces the nuclear accumulation of RelA. (A) COS cells were transfected with RelA together with cDNA expression vectors encoding either GFP (a to c) or p50-GFP (d to f). The cells were stained with the C-terminal specific anti-RelA antibody plus Texas red-conjugated rabbit IgG. The expression of RelA and GFP or p50-GFP in the same cells was visualized with rhodamine (upper panels) and FITC (middle panels) filters, respectively. The nuclei of the cells were visualized by Hoechst staining (lower panels). Note that most of the cells were cotransfected. A cell expressing only RelA is indicated by the arrow. (B) COS cells were transfected with RelA and p50-GFP-NES, and the transfected cells were subjected to immunofluorescence as described above. A cell expressing only RelA is indicated by the arrow, which shows cytoplasmic expression of RelA.

Free IB accumulates in the nucleus. A recent study suggested that IB contains a NES which mediates active nuclear export in the Xenopus oocyte (1). To examine whether the nuclear export of IB is a dominant event in its subcellular distribution in mammalian somatic cells, immunofluorescence assays were performed with an IB-GFP fusion protein. Interestingly, the expressed IB fusion protein was predominantly detected in the nucleus (Fig. 6A). As previously demonstrated (21, 61), when IB was coexpressed with RelA, the nuclear expression of both proteins was largely blocked (Fig. 6A). Furthermore, when IB was coexpressed with RelA in the presence of p50, all three proteins were completely excluded from the nucleus (Fig. 6B and data not shown). Thus, although p50 promotes the nuclear expression of free RelA (Fig. 5A and 6A), it is unable to override the inhibitory function of IB. Therefore, regulation of RelA subcellular localization by p50 likely occurs after the degradation of IB during a cellular stimulation.

View larger version (27K): [in this window] [in a new window]   FIG. 6.   Free IB accumulates in the nucleus but is excluded from the nucleus when coexpressed with RelA and p50. (A) COS cells were transfected with an expression vector encoding the IB-GFP fusion protein either alone (left panels) or together with RelA (right panels). The transfected cells were subjected to immunostaining with anti-RelA, and the subcellular localization of IB-GFP and RelA was visualized by a fluorescence microscope with FITC (upper panels) and rhodamine (middle panels) filters, respectively. DNA staining is shown in the lower panels. (B) COS cells were transfected with p50-GFP together with RelA (left panels) or p50-GFP together with RelA and IB (right panels). The cells were subjected to immunofluorescence analyses as described above, and the subcellular localization of p50-GFP and RelA was visualized with FITC (upper panels) and rhodamine (middle panels) filters, respectively. DNA staining is shown in the lower panels.

	DISCUSSION

Top Abstract Introduction Materials and Methods Results Discussion References

The biological activity of NF-B is regulated at the level of subcellular localization. NF-B is normally sequestered in the cytoplasmic compartment by physical association with IB, which specifically binds to and masks the NLS of both RelA and p50 subunits of NF-B (7, 21, 61). Upon cellular stimulation, IB is rapidly degraded, and the liberated NF-B heterodimer concomitantly moves to the nucleus. Since both RelA and p50 contain an NLS, it is generally believed that both of these proteins will localize to the nucleus in the absence of IB. When expressed in various cell types, p50 is indeed predominantly nuclear (8, 21, 25). Unexpectedly, however, a large proportion of RelA is retained in the cytoplasm even when it is expressed in the absence of IB (Fig. 1) (21). This finding prompted us to explore additional mechanisms regulating the subcellular localization of RelA. Our studies demonstrate that RelA contains a leucine-rich sequence homologous to the recently characterized NES (22). This NES-like sequence is both required and sufficient for maintaining the whole-cell expression pattern of RelA. When fused to p50, the RelA NES is able to alter the subcellular localization pattern of p50 from nuclear to whole cell, suggesting that this NES also functions on heterologous proteins. Unlike IB and the C-terminal sequences of p105 and p100 (7, 32, 39, 61), the RelA NES-like sequence does not inhibit the nuclear import of RelA or heterologous proteins since these proteins accumulate in the nucleus when nuclear export is blocked by LMB. The LMB-induced nuclear accumulation of RelA and its derivatives is insensitive to the protein synthesis inhibitor cycloheximide (data not shown), suggesting that these NES-containing proteins are continuously shuttling rather than just passing through the nucleus after being newly synthesized.

The finding that LMB causes the nuclear accumulation of RelA WT is somewhat surprising since RelA WT induces expression of endogenous IB (Fig. 4A). One possible explanation is that a significant proportion of RelA may be present as free forms in overexpressed cells, which would translocate to the nucleus and accumulate there in the presence of LMB. Another possibility is that the dynamic nature of the RelA-IB interaction may allow the occasional release and nuclear translocation of RelA. Of course, the moderate inhibition of IB synthesis observed in cells treated with LMB (Fig. 4B) may also contribute in part to the nuclear expression of RelA WT. In any case, our LMB dose-responsive assays show that RelA WT appears to be less sensitive to LMB than p65(1-450) and p50-GFP-NES. At a low concentration (10 ng/ml), LMB induced the complete nuclear expression of the truncated RelA and p50-GFP-NES but only caused a partial effect on RelA WT (data not shown). The lower LMB sensitivity of RelA WT may reflect the effect of endogenous IB on RelA nuclear import. Nevertheless, given the strong inhibitory effect of LMB on the cytoplasmic expression of various RelA mutants and p50-GFP-NES, which do not induce IB expression, it is likely that the cytoplasmic expression of free RelA is at least partially contributed to by its active nucleus export.

What biological roles can the RelA NES play? First, the NES sequence may function to restrict the nuclear translocation of RelA in the absence of a partner like p50. Indeed, the RelA homodimer is rare in most cell types, whereas the p50-RelA heterodimer is predominant. Second, the NES of RelA may facilitate the nuclear export of RelA and p50 when bound to IB in the nucleus. In this regard, a recent study suggests that IB contains a NES, which mediates nuclear export of IB in the Xenopus oocyte (1). Surprisingly, we have shown that an IB-GFP fusion protein accumulates in the nucleus when expressed in COS cells (Fig. 6). Nuclear accumulation of transfected IB has also been observed in other studies (15, 61), although a whole-cell expression pattern can be detected under different transfection conditions (43, 55). These studies suggest that a high efficiency of IB nuclear export may require its binding to RelA, which provides a second NES. These findings support the notion that newly synthesized free IB efficiently enters the nucleus. Binding of IB to RelA and p50 may not only block the nuclear translocation of these proteins but also promote the nuclear export of the inactive NF-B-IB complex. In this regard, the NLS of IB is located in its second ankyrin repeat (43). Notably, recent structural studies of the IB-RelA complex suggest that the first and second ankyrin repeats of IB are involved in extensive interaction with the NLS region of RelA (3, 27, 29). IB forces the otherwise unstructured RelA NLS and flanking sequences into an -helical conformation that may not be recognized by nuclear import proteins (3). Thus, formation of the NF-B-IB complex will mask the NLS of both IB and the NF-B subunits. In contrast to the NLS, the putative NES of RelA is located outside of the region involved in binding to IB (3, 27, 29). It is likely that the NES-like sequence of RelA is exposed when RelA is bound by IB. However, this notion needs to be confirmed by further biochemical or structural analysis since the RelA NES region is not included in the crystal structure of the RelA-IB complex. The NES of IB is located in its sixth ankyrin repeat (1), which is involved in its physical interaction with RelA and p50 (27, 29). Indeed, the NES (previously named the QL-rich region) of IB is essential for its physical association with RelA (50). It remains to be determined whether the NES of IB or that of RelA or both are required for the nuclear export of the NF-B-IB complex.

An interesting finding of this study is that p50 promotes the nuclear accumulation of RelA. When coexpressed in cells, RelA and p50 are colocalized in the nucleus, while free RelA exhibits a whole-cell expression pattern. The mechanism mediating this function of p50 remains unclear. Since p50 contains an NLS but lacks a NES, the RelA-p50 heterodimer possesses a higher NLS-to-NES ratio (2:1) than the RelA-RelA homodimer (2:2). However, this structural difference does not seem to contribute to the strong nuclear distribution activity of the RelA-p50 heterodimer. As shown in Fig. 5B, fusion of the RelA NES to p50 did not affect the activity of p50 to stimulate the nuclear accumulation of RelA, although the NES did cause cytoplasmic expression of free p50 (Fig. 3B). Additionally, the subcellular localization of p50 and RelA appear to be mutually regulated, since both p50-NES and RelA are located in the nucleus when they are coexpressed (Fig. 5B). Thus, the mechanism by which p50 promotes RelA nuclear localization appears to be complex. One possibility is that heterodimer formation induces conformational changes in RelA and p50, which may result in the masking of the NES and better exposure of the NLS of these proteins. Alternatively, the combination of a p50 NLS with a RelA NLS may favor the nuclear localization of the NF-B heterodimer. Nevertheless, our finding suggests that heterodimer formation serves as a step in the regulation of NF-B nuclear expression.